Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG

NCT00818441 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00818441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00818441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
March 11, 2009
Completion date
April 30, 2015
Enrollment
119 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell